Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Jason Bacharach"'
Autor:
Jason Bacharach, Long V. Doan, Kerry G. Stephens, Dale W. Usner, Angela C. Kothe, L. Jay Katz, Tomas Navratil
Publikováno v:
Ophthalmology and Therapy, Vol 13, Iss 9, Pp 2357-2367 (2024)
Abstract Introduction This study was conducted to analyze and compare the intraocular pressure (IOP) treatment effect of the slow-eluting (SE) travoprost intracameral implant to the IOP treatment effect of topical prostaglandin analog (PGA) monothera
Externí odkaz:
https://doaj.org/article/c49e87653c9144ec87f3d9d99da00a54
Publikováno v:
Therapeutic Advances in Ophthalmology, Vol 16 (2024)
The glaucoma treatment paradigm is starting to change from a more reactive approach that relies on topical medications to a more proactive approach that leverages procedural interventions. This evolution toward interventional glaucoma has been enable
Externí odkaz:
https://doaj.org/article/7a39790f978640df8cb8f034376cafc7
Autor:
Barry A Schechter, Maitee Urbieta, Jason Bacharach, Melissa Toyos, Robert Smyth-Medina, Brittany Mitchell, Jodi I Luchs
Publikováno v:
Clinical Ophthalmology.
Barry A Schechter,1 Maitee Urbieta,2 Jason Bacharach,3 Melissa Toyos,4 Robert Smyth-Medina,5 Brittany Mitchell,2 Jodi I Luchs6 1Florida Eye Microsurgical Institute, Boynton Beach, FL, USA; 2Medical Affairs North America, Sun Pharmaceutical Industries
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1fcd58a732498b1c64142974be72c43
https://www.dovepress.com/effect-of-otx-101-in-patients-with-dry-eye-disease-at-day-14-of-treatm-peer-reviewed-fulltext-article-OPTH
https://www.dovepress.com/effect-of-otx-101-in-patients-with-dry-eye-disease-at-day-14-of-treatm-peer-reviewed-fulltext-article-OPTH
Autor:
Jason Bacharach, Robert Smyth-Medina, Shane R Kannarr, David Wirta, Michael S Korenfeld, Charles B. Slonim, Mark Jaros, Shane Foster
Publikováno v:
Clinical Ophthalmology (Auckland, N.Z.)
Purpose An oxymetazoline 0.1% ophthalmic solution was recently approved for treatment of acquired blepharoptosis in adults. This study’s objective was to evaluate the safety profile of oxymetazoline 0.1% when administered once daily for 14–84 day
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e4e23d71c87b1eb0197bf4e293f138e
https://doi.org/10.2147/opth.s322326
https://doi.org/10.2147/opth.s322326
Autor:
Robert N. Weinreb, Jason Bacharach, Jacob W. Brubaker, Felipe A. Medeiros, Marina Bejanian, Paula Bernstein, Michael R. Robinson
Publikováno v:
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::216974b647fc671a6f0c0a8333773fae
https://pubmed.ncbi.nlm.nih.gov/36378864
https://pubmed.ncbi.nlm.nih.gov/36378864
Autor:
Da Wen Lu, Tin Aung, Michael S. Kook, Louis B. Cantor, Ki Ho Park, Toru Nakazawa, Jason Bacharach, Makoto Aihara
Publikováno v:
Expert Review of Ophthalmology. 16:243-250
Introduction: Current medical therapy for glaucoma consists of topical agents that lower intraocular pressure (IOP). Prostaglandin F2α analogues, the most commonly used class of IOP-lowering drugs,...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcc2b097082c0b9a3ac3b4fc8f4fbf8b
https://doi.org/10.1080/17469899.2021.1935241
https://doi.org/10.1080/17469899.2021.1935241
Autor:
Jason Bacharach, Cathleen McCabe, Mitchell Jackson, Sanjay Rao, I Paul Singh, Sebastian Heersink, Nathan Radcliffe, Robert Weinstock, Dario Paggiarino, Keyur Patel
Publikováno v:
Clinical Ophthalmology.
Jason Bacharach,1 Cathleen McCabe,2 Mitchell Jackson,3 Sanjay Rao,4 I Paul Singh,5 Sebastian Heersink,6 Nathan Radcliffe,7 Robert Weinstock,8 Dario Paggiarino,9 Keyur Patel9 1North Bay Eye Associates Petaluma, Petaluma, CA, USA; 2The Eye Associates,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ea73f0eea17c11d7e044699349ce6fc
https://www.dovepress.com/first-real-world-multicenter-post-marketing-retrospective-study-of-dex-peer-reviewed-fulltext-article-OPTH
https://www.dovepress.com/first-real-world-multicenter-post-marketing-retrospective-study-of-dex-peer-reviewed-fulltext-article-OPTH
Publikováno v:
Journal of Cataract and Refractive Surgery
A sustained-release intraocular formulation of dexamethasone for the treatment of postsurgical inflammation had a similar IOP safety profile to that of a topical corticosteroid among patients undergoing cataract surgery.
Purpose: To characterize
Purpose: To characterize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47dce56fc1c03ee2c53b667a682457d2
http://europepmc.org/articles/PMC7889288
http://europepmc.org/articles/PMC7889288
Autor:
John Sheppard, Jason Bacharach, Shane R Kannarr, Abayomi Ogundele, Jodi Luchs, Charles Darby, Angela Justice, Ranjan Malhotra
Publikováno v:
Eye & Contact Lens: Science & Clinical Practice. 46:S14-S19
OTX-101 (CEQUA™) is approved in the United States for treatment of keratoconjunctivitis sicca (KCS). This pooled analysis of 2 studies (phase 2b/3 and phase 3) evaluates the efficacy and safety of OTX-101 0.09% in the intent-to-treat (ITT) populati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7932422294c13d06007e54730e4711e
https://doi.org/10.1097/icl.0000000000000636
https://doi.org/10.1097/icl.0000000000000636
Publikováno v:
Clinical Ophthalmology. 14:119-126
Dry eye disease (DED) is a multifactorial disease of the ocular surface characterized by loss of homeostasis of the tear film and accompanied by ocular signs and symptoms such as corneal and conjunctival damage, patient discomfort, and visual disturb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca5b93a076e69105e3f94e6195b95e22
https://doi.org/10.2147/opth.s228838
https://doi.org/10.2147/opth.s228838